ANIX
Anixa Biosciences Inc (ANIX
NASDAQ · Healthcare · Biotechnology · US
$2.61
−2.25%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +9.2%
- EBIT
- +8.4%
- EPS
- —
- Free cash flow
- -7.8%
- Operating cash flow
- -7.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -4.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.2%
- EBIT
- +15.4%
- Net income
- +13.0%
- EPS
- +12.8%
- Free cash flow
- +2.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026